Invivyd Unveils Measles Antibody Candidate VMS063 at IDWeek 2026

Invivyd announced preclinical data supporting VMS063, which the company calls a novel, potential first- and best-in-class monoclonal antibody for the potential treatment and prevention of measles.¹

The data were presented at IDWeek 2026, held October 21-24, 2026, in Washington, DC. VMS063 is a highly potent, half-life-extended, high-resistance barrier measles monoclonal antibody candidate that could be the first precision therapy for measles and could be offered as an alternative or addition to the current measles vaccine. The company positioned VMS063 as an option that could help strengthen immunization and offer people an alternative to the measles, mumps, and rubella (MMR) vaccine as cases continue to rise.¹ It’s also notable given President Donald J. Trump’s recent executive order directing HHS to reform the childhood immunization schedule once again. That order called for separating the MMR vaccine into 3 single-disease vaccines, with the order claiming the separated shots would be safer than the current combined vaccine. Under the order, single-disease products would be used once they were domestically available.²

“Despite continued transmission of measles globally and a reemergence in the United States, physicians who see measles patients have long lamented that there are no targeted approved treatments for measles. More generally, there has been little, if any, innovation in how we prevent and treat measles since 1963,” Michael Mina, MD, PhD, chief medical officer and chief epidemiologist of Invivyd and a widely cited measles researcher, said in a press release. “As we see more and more cases, it’s clear that Americans, as well as the international community, need additional prevention options for measles as well as a specific treatment.”¹

Why Measles Needs a Targeted Treatment Option

As of October 2026, US measles disease burden is nearly double that seen in 2025, and more than 9 million school-aged children are estimated to be unprotected against measles, according to Invivyd.¹ There are currently no FDA-approved treatments for measles. Treatment is limited to supportive or indirect interventions, such as vitamin A, intramuscular immunoglobulin, and pooled intravenous immunoglobulin, all with varying levels of efficacy.³

In the study, VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants. It also demonstrated attractive biophysical properties that support its potential use for both treatment and prevention, including pre- and post-exposure prophylaxis, of measles.¹ As there are currently no directed antiviral treatments available for measles, monoclonal antibodies such as VMS063 have the potential to provide direct, durable, and equitable immunity.³

VMS063 targets the measles fusion (F) protein and is designed to lock it into a pre-fusion configuration, preventing cell entry, similar to approved pediatric respiratory syncytial virus monoclonal antibodies.¹

VMS063 Neutralized Dominant B3 and D8 Measles Genotypes

The developability of VMS063 was evaluated by determining the melting temperature (T_m) using nano differential scanning fluorimetry (1 mg/mL in 1×PBS pH 7.4), hydrophobicity using hydrophobic interaction chromatography, and aggregation potential using dynamic light scattering.³

VMS063 demonstrated stability comparable to prior therapeutic monoclonal antibodies, with a T_m greater than 70°C and a low propensity to aggregate. Cryogenic electron microscopy showed that it targeted the measles virus fusion protein (MeV-F) at a highly conserved epitope. It also showed high potency, with mean 50% neutralization at single-digit ng/mL concentrations: 1.4 ng/mL and 4.2 ng/mL in pseudovirus and authentic MeV neutralization assays, respectively, against historical as well as the highest circulating contemporary variants, genotypes B3 and D8.³

The researchers noted that the findings are based on in vitro neutralization data and may not directly translate to clinical efficacy. The work was funded by Invivyd, and the authors are current or former Invivyd employees.³ Invivyd plans to develop VMS063 in either intramuscular or subcutaneous forms and has begun manufacturing scale-up toward clinical development in 2027.¹

“A molecule like VMS063 has the potential to transform the measles landscape by leveraging the extraordinary potential of monoclonal antibodies that can, with one molecule, provide both prevention and treatment to fill these gaps,” Mina said. “We are excited to interact with the scientific and public health community at IDWeek 2026, as well as leaders across public health more generally, and we are rapidly advancing this program toward clinical development.”¹

References

1. Invivyd presents VMS063, a potential best-in-class monoclonal antibody candidate for the treatment and prevention of measles, at IDWeek 2026. News release. Invivyd. October 21, 2026. Accessed November 2, 2026. https://investors.invivyd.com/news-releases/news-release-details/invivyd-presents-vms063-potential-best-class-monoclonal-antibody

2. McCrear S. Trump childhood vaccine order: what it means for parents and payers. AJMC. August 11, 2026. Accessed November 2, 2026. https://www.ajmc.com/view/trump-childhood-vaccine-order-what-it-means-for-parents-and-payers

3. Martin RNA, Chupp D, Powers C, Gao F, Mina M, Allen R. VMS063: a novel, highly potent, half-life extended, pan-measles variant investigational antibody. Presented at: IDWeek 2026; October 21-24, 2026; Washington, DC. Poster P-2082.